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Summary
Objectives: The aim of this study was to describe the antimicrobial prescription
patterns of patients with hematological malignancies who developed febrile neu-
tropenia (FN) at Sultan Qaboos University Hospital (SQUH) in Oman.
Methods: This was a retrospective observational study covering a period of 3 years
(January 2007—February 2010). FN episodes were studied in patients with hemato-
logical malignancies in three different wards at SQUH.
Results: A total of 176 FN episodes were analyzed. Overall, 64% of the 107 patients
studied experienced at least 2 episodes during the analysis period. Approximately,
69% of the febrile neutropenia episodes had severe neutropenia. The duration of
neutropenia was less than 1 week in the majority of the episodes (57%). The mean
duration of treatment was approximately 7 days, with no signiﬁcant difference
between specialties or different types of malignancies. Only 34 (19%) episodes had
positive cultures, and most of these were from blood samples (30 episodes, 88%).
The majority of isolates were gram-negative organisms (63%). The initial empirical
treatment included monotherapy (37%), dual therapy (60%) and triple therapy (3%).
Conclusions: This study demonstrates that there is a large variation in the antimicro-
bial treatment of FN episodes in patients with hematological malignancies at SQUH.
All chosen drugs were within international guideline recommendations.
© 2013 King Saud Bin Abdulaziz University for Health Sciences. Published by Elsevier
Ltd. All rights reserved.
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dntimicrobial prescription patterns of patients with
ntroduction
nfections due to neutropenia are common in
atients with hematological malignancies receiving
hemotherapy. Fever is usually the ﬁrst and may be
he only sign of infection in neutropenic patients.
eutropenia is deﬁned as an absolute neutrophil
ount (ANC) <500 cells/mm3 or <1000 cells/mm3
hat decreases to <500 cells/mm3 within 48 h
1]. The term febrile neutropenia (FN) describes
he occurrence of fever (temperature≥ 38.3 ◦C or
38.0 ◦C for at least 1 h) in patients with neutrope-
ia [1].
Cancer chemotherapy is the most common cause
f FN. Studies have shown that up to 25% of
atients treated with chemotherapy experience a
N episode, and the frequency of FN is higher in
ematological malignancies [2]. The majority of
eutropenic episodes occur within the ﬁrst 14 days
f chemotherapy [3]. FN is associated with signiﬁ-
ant morbidity, mortality and cost [4,2]. Morbidity
s usually caused by infections during severe and
rolonged episodes of neutropenia. Patients with
N are at risk of infection from all types of microbes
ncluding gram-positive and gram-negative bacte-
ia, fungi and viruses. Because FN is a potentially
ife-threatening condition and as the progression of
nfection in neutropenic patients can be rapid, such
atients should receive empirical antibiotic ther-
py immediately after blood cultures are obtained
nd before any other diagnostic procedures are per-
ormed.
The present study describes the pattern of
ntimicrobial therapy for FN in patients with hema-
ological malignancies at Sultan Qaboos University
ospital (SQUH), Sultanate of Oman.
atients and methods
his study was a retrospective observational study
f antimicrobial therapy for FN episodes in patients
ith hematological malignancies (leukemias, lym-
homas and myelomas) from the adult hematology,
ediatric hematology and adult oncology depart-
ents at SQUH, covering the period from January
007 to February 2010. Neutropenia was deﬁned as
n absolute neutrophil count (ANC) <500 cells/mm3
r as an ANC< 1000 cells/mm3 that decreased to
500 cells/mm3 within 48 h. Fever was deﬁned as
single temperature reading ≥38.3 ◦C or a reading
◦38.0 C for at least 1 h. Oral temperatures were
ecorded for all patients. In addition, the axillary
emperature was recorded for pediatric patients.
he severity of neutropenia was classiﬁed as mild
o
3
t
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ANC between 1000 and 1500 cells/mm3), moder-
te (ANC between 500 and 1000 cells/mm3), severe
ANC less than 500 cells/mm3) or profound (ANC less
han 100 cells/mm3) [5].
Data were collected for each FN episode. This
ncluded demographic data; the general proﬁle of
N episodes, which included the onset of neu-
ropenia; the absolute neutrophil count (ANC); the
everity of neutropenia and degree/duration of
ever; the details of antimicrobial therapy; blood,
putum and urine culture results; and the patient’s
utcome. The study was approved by the College of
edicine’s research and ethics committee at SQU.
The data were coded and entered into the
tatistical Package for the Social Sciences (SPSS)
ersion 16, and the differences between groups
ere tested for statistical signiﬁcance using the 2
est for categorical variables and Student’s t-test
or independent samples with continuous variables.
p-value < 0.05 was considered signiﬁcant at the
5% conﬁdence interval.
esults
total of 176 febrile neutropenic (FN) episodes
ere identiﬁed in 107 patients. The mean age
f the patients was 22.5 years (SD± 20.8 years),
ith 59 males (55.1%) and 48 females (44.9%).
eukemia was the main underlying malignancy
ccurring in 78.5% of these patients, with acute
ymphocytic leukemia being the most common
51.4%). In addition, 18.7% and 2.8% of the patients
ad lymphoma or multiple myeloma, respec-
ively. Sixty-nine patients (64.5%) suffered two FN
pisodes during the study period.
roﬁle of febrile neutropenia episodes
inety-eight (55.5%) of the 176 episodes occurred
n male patients, and the majority (83.0%) occurred
n leukemic patients. The mean hospital stay for
hese episodes was 24.9 days (SD± 18.2 days).
he mean duration of hospital stay for episodes
eveloped during a hospital stay was 34.3 days
ompared to 12.3 days for episodes that lead
o admission (p-value < 0.001). Eighty-six episodes
49%) were treated in the Pediatric Hematology
epartment, 77 (44%) in the Adult Hematology
epartment and only 13 (7%) in the Adult Oncol-
gy department. The mean body temperature was
8.7 ◦C (range 38.3—40.4 ◦C) with a mean dura-
ion of 1.6 days (SD± 1.3 days). The mean ANC
as 309 cells/mm3 (SD± 207). Approximately 69%
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Table 1 Positive blood culture results (n = 30) for
febrile neutropenia episodes.
Coagulase-negative Staphylococcus 7
Escherichia coli 6
Klebsiella pneumonia 5
Pseudomonas aeruginosa 5
Staphylococcus aureus 3
Acinetobacter baumannii 1
Viridans streptococcus 1
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AMorganella morgani 1
Streptococcus gordonii 1
(n = 121) of the FN episodes had severe neutropenia
(ANC < 500 cells/mm3), and 31.2% (n = 55) of the FN
episodes hadmoderate neutropenia (ANC 500—1000
cells/mm3).
The duration of neutropenia was less than 1 week
in most episodes (57%), with 32% of the episodes
lasting 7—14 days. FN developed during a hospital
stay in 101 (57%) out of the 176 FN episodes, and the
remaining 75 (43%) episodes involved patients who
were admitted because of FN. Granulocyte-colony
stimulating factor was used in several patients
as per standard protocols, mainly for hemopoietic
malignancies. However, the impact of granulocyte-
colony stimulating factor on neutropenia severity
and duration was not addressed in this study.
Proﬁle of microorganisms
Only 34 (19%) of the episodes were associated with
positive culture results, and most of these were
obtained from blood samples (30 episodes). The
majority of isolates were gram-negative organisms
(62.5%). The most common isolated pathogen from
the blood samples was coagulase-negative Staphy-
lococcus followed by Escherichia coli (Table 1).
None of the patients were known to be infected
with multi-drug resistant pathogens.
Empirical antimicrobial therapy used in
FN episodes
The mean duration of inpatient antibiotic treat-
ment was 7.3 days (SD± 3.2; range 2—21 days).
There was a positive association between the
neutropenia duration and treatment duration (p-
value < 0.001). There was no signiﬁcant difference
in the duration of treatment between specialties
(p-value = 0.870) or between the different types of
malignancies (p-value = 0.915). As there is no uni-
ﬁed SQUH protocol for the empirical antimicrobial
A
o
tigure 1 Antibiotics used for monotherapy in febrile
eutropenia episodes according to specialty.
reatment of FN, different department-driven pro-
ocols were employed and recommendations from
nfectious disease specialists were used as a
tandard reference.
The initial empirical antimicrobial treatment
anged from monotherapy to triple therapy, with
7% of patients treated with monotherapy, 60%
reated with dual therapy and only 3% treated with
riple therapy. Only three classes of antibiotics
ere used for monotherapy in the treatment of FN
pisodes: carbapenems (meropenem or imipenem)
47.6%), fourth-generation cephalosporins
cefepime) (40%) and antipseudomonal peni-
illin [tazocin (piperacillin + tazobactam)] (12.3%).
s shown in Fig. 1, there was a signiﬁcant variation
n the choice of monotherapy according to the
pecialties (p-value < 0.001). None of the patients
ere given the antibacterial prophylaxis.
The combination of tazocin
piperacillin + tazobactam) plus an aminogly-
oside was used in 80% (n = 105) of the FN episodes.
n patients who had two FN episodes, there was no
igniﬁcant difference in the initial empirical treat-
ent between the ﬁrst and the second episode.
he study results did not indicate any signiﬁcant
ifference between monotherapy and combination
herapy in terms of neutropenia severity and
uration, treatment changes, positive culture
r episode outcome. Table 2 summarizes the
ntibiotics used for the treatment of FN episodes
ccurring during this study with the frequency of
se according to specialty.
ntimicrobial modiﬁcationntimicrobial modiﬁcations were all additions and
ccurred in 29 (16.5%) FN episodes. Twelve addi-
ions were added to monotherapies, and 17 were
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Table 2 First-line antibiotic therapy used by three different specialties.
Antimicrobial regimen Total Pediatric
hematology (86)
Adult
hematology (77)
Adult oncology
(13)
Meropenem/imipenem 31 3 26 2
Cefepime 26 24 2 0
Tazocin (piperacillin + tazobactam) 8 0 3 5
Meropenem+ gentamicin 7 0 7 0
Meropenem+amikacin 3 0 2 1
Meropenem+ vancomycin 3 0 3 0
Meropenem+ teicoplanin 1 0 0 1
Meropenem+ ciproﬂoxacin 3 0 3 0
Tazocin (piperacillin + tazobactam) + gentamicin 82 56 25 1
Tazocin (piperacillin + tazobactam) + amikacin 2 1 0 1
Tazocin (piperacillin + tazobactam) + ciproﬂoxacin 4 0 3 1
Meropenem+ gentamicin + vancomycin 1 0 1 0
Meropenem+ gentamicin + teicoplanin 1 0 0 1
Meropenem+amikacin + vancomycin 1 0 1 0
Meropenem+amikacin + teicoplanin 1 1 0 0
Tazocin (piperacillin + tazobactam) + gentamicin 2 1 1 0
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[+ vancomycin
dded to combination therapies. The most common
pproach was to add a glycopeptide with or without
n antifungal to the ongoing regimen. The gly-
opeptides were added following persistent fever
o initial regimens regardless of the presence or
bsence of certain infections. All antifungal agents
dded were due to persistent fever.
The mean time for starting antifungal therapy,
ounting from the ﬁrst day of fever, was 6.7 days
ranging from 2 to 9 days). Four of the additions
ere in response to culture results. The remaining
ndications for antimicrobial additions were not
eported in clinical notes on the day of starting
herapy. Out of the 176 FN episodes, 6 (3.4%) deaths
ccurred. Four of the episodes produced positive
ulture results. However, it should be noted that
nfection-related mortality could not be addressed
ith certainty in this study.
ndividual antibiotic sensitivity in
ebrile neutropenia episodes
able 3 lists the sensitivity patterns of the major
solated organisms to the individual antimicro-
ials used in the treatment of FN. The organism
ost commonly isolated from blood was coagulase-
egative Staphylococcus. All seven isolates were
ensitive to vancomycin.
However, six of the seven isolates were resistant
o gentamicin. Four E. coli isolates were resistant to
azocin (piperacillin + tazobactam), and three iso-
ates were resistant to ciproﬂoxacin.
t
o
P
siscussion
he present retrospective study focused on the pat-
ern of antimicrobial treatment for FN in patients
ho received chemotherapy for hematological
alignancies at SQUH. Although the study was not
esigned to determine the incidence of FN in these
atients, the results suggest that the incidence of
N is high compared to other studies [4], as 69 of the
07 patients (64%) experienced at least 2 episodes
uring the analysis period. FN was also associated
ith high morbidity (mean hospital stay of 25 days)
nd mortality (6 out of 107 patients; 5.6%). The
tudy indicates a signiﬁcant variation in the choice
f initial empirical antimicrobial drugs between the
hree specialties managing these episodes. How-
ver, all chosen drugs were within international
uidelines and recommendations [1,4,6—8].
The use of combination therapy for FN at SQUH
ppears to be higher than expected from the
nternational guidelines and evidence from the
iterature [1,4,6—8]. A meta-analysis comparing
onotherapy regimens with combination therapy
egimens for the treatment of FN found no differ-
nce in the overall response (resolution of fever
r infection without initial regimen modiﬁcation,
esponse in documented gram-negative infections,
verall survival and infection-related mortality)
9].
Combination therapy is recommended whenhere is high suspicion (based on local epidemiol-
gy) of resistant gram-negative infections, such as
seudomonas aeruginosa, or when there is severe
epsis or septic shock [1]. To our knowledge, there is
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Table 3 Sensitivity of blood culture isolates to antimicrobials used in the treatment of febrile neutropenia.a
Coagulase-negative
Staphylococcus
E. coli Klebsiella
pneumonia
Pseudomonas
aeruginosa
Staphylococcus
aureus
Total isolates 7 6 5 5 3
Meropenem 1 S 2 S 2 S 2 S 1 S
1 R 1 R 3 NT 3 NT 2 NT
5 NT 3 NT
Imipenem 7 NT
Cefepime 7 NT 1 S 1 S
1 R 4 NT
4 NT
Tazocin (piperacillin + tazobactam) 7 NT 1 S 3 S 4 S
4 R 2 NT 1 R
1 NT
Gentamicin 1 S 3 S 5 S 5 S 1 S
6 R 2 R 2 NT
1 NT
Amikacin 7 NT 2 S 2 S 1 S
1 R 3 NT 4 NT
3 NT
Ciproﬂoxacin 2 S 1 S 1 S 2 S
1 R 3 R 4 NT 3 NT
4 NT 2 NT
Vancomycin 7 S 1 S
2 NT
Teicoplanin 1 S
1 R
5 NT
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va S, sensitive; R, resistant; NT and blank cells, not tested.
no published information on the local epidemiology
of infections in neutropenic patients in Oman.
In addition, the pattern of local antimicrobial
resistance in FN has not been identiﬁed. The
higher frequency of combination therapy use is
in accordance with SQUH guidelines for the man-
agement of FN. The latest edition (2006) of the
hospital-wide SQUH Antibiotics Handbook recom-
mends dual therapy as the ﬁrst-line choice for FN,
with monotherapy as an alternative. In addition,
specialty-speciﬁc local protocols (management of
febrile neutropenia protocol in pediatrics and in
adult oncology) recommend dual therapy as the
ﬁrst-line choice for the treatment of FN. The higher
use of combination therapy is also similar to ﬁnd-
ings from other studies from different parts of the
world. Studies from Australasia [6], Korea [7] and
the United Kingdom [8] have reported that tazocin
[piperacillin + tazobactam] plus gentamicin is the
most common empirical therapy in the manage-
ment of FN.
This study revealed that the antibiotics used
as monotherapy for FN at SQUH were car-
bapenem (mainly meropenem), cefepime, and
tazocin (piperacillin + tazobactam). All of these
antibiotics are recommended by the international
e
c
s
duidelines [carbapenem, cefepime, ceftazidime or
azocin (piperacillin + tazobactam)] [1,10]. How-
ver, ceftazidime has not been used at SQUH since
006 due to Pseudomonas resistance (personal com-
unication).
The choice of empirical therapy should be based
n a variety of factors such as patient infection
isk, known local epidemiology of infections, local
ntimicrobial sensitivity and resistance patterns
nd available evidence from the literature [11]. The
isk of infection depends on the severity of neu-
ropenia [4]. This study revealed that the choice
etween monotherapy and dual therapy was inde-
endent of the severity of neutropenia among the
ifferent specialties.
onclusions
he current study indicates that there is a large
ariation in the antimicrobial treatment of FN
pisodes in patients with hematological malignan-
ies at SQUH. However, due to the nature of the
tudy, it was not possible to determine the inci-
ence of FN or the factors affecting the choice
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f antimicrobial treatment. Because a knowledge
f local microbial isolates and resistance pat-
erns is very important in deciding upon the
rst choice of empirical antimicrobial therapy for
N, this retrospective analysis highlights the need
o prospectively determine the factors that may
nﬂuence the choice of FN antimicrobial therapy,
ncluding the microbial proﬁle, local antimicrobial
ensitivity and resistance patterns, so that the hos-
ital can develop local practice guidelines based on
ocal evidence. It is also important to determine the
ncidence and outcome of FN in patients treated at
QUH to provide optimal therapy.
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